<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292082</url>
  </required_header>
  <id_info>
    <org_study_id>2014-018</org_study_id>
    <nct_id>NCT02292082</nct_id>
  </id_info>
  <brief_title>The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)</brief_title>
  <acronym>ACB PAI</acronym>
  <official_title>The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee replacement is associated with severe post-operative pain. The purpose of this
      study is to compare two methods of treatment for pain control following Total Knee
      Replacement with an accelerated physical therapy protocol to aid the achievement of rehab
      milestones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 106 patients undergoing total knee arthroplasty will be randomized into two
      groups: one to receive only Periarticular injections and the other periarticular injections
      AND adductor canal block.

      Patients will be asked their numeric pain scores before surgery as baseline and at 24 and 48
      hours post-operation. Patients also will be asked questions from painOUT questionnaire at 24
      and 48 hours.

      Time to reach discharge criteria based on physical therapy assessments will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Meet Physical Therapy Discharge Criteria</measure>
    <time_frame>Participants will be followed for the duration of 3 days post operatively in the hospital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale (NRS) Pain Scores</measure>
    <time_frame>Participants will be followed for the duration of 2 days post operatively in the hospital</time_frame>
    <description>On a scale of 0 - 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Participants will be followed for the duration of 2 days post operatively in the hospital</time_frame>
    <description>Measured in morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3-4 days</time_frame>
    <description>Measured in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome Questionnaire (painOUT)</measure>
    <time_frame>Participants will be followed for the duration of 2 days post operatively in the hospital</time_frame>
    <description>Measures: least and worst pain in the last 24 hours on a scale of 0 to 10, incidence of nausea, drowsiness, dizziness, and itchiness (scale of 0 to 10) and patient satisfaction with pain treatment (scale of 0 to 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score (KSS)</measure>
    <time_frame>Post operatively at approximately 6 weeks after their surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o'clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>8 MHz. Chiba needle, 22 G / 4 inches</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteoarthritis scheduled for primary tricompartmental total knee
             arthroplasty with a participating surgeon

          -  Age 18 to 80 years

          -  Planned use of regional anesthesia

          -  Ability to follow study protocol

          -  English speaking (secondary outcomes include questionnaires validated in English only)

        Exclusion Criteria:

        Hepatic or renal insufficiency Patients younger than 18 years old and older than 80
        Patients intending to receive general anesthesia Patients planning to go to rehab post
        operatively Patients scheduled to go into the OR after 1 pm Allergy or intolerance to one
        of the study medications Patients with an ASA of IV Chronic gabapentin/pregabalin use
        (regular use for longer than 3 months) Chronic opioid use (taking opioids for longer than 3
        months) Diabetes Patients on workers compensation or disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique A Goytizolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nerve Block</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Knee Replacement, Total</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

